An Open-label Exploratory Phase II Study of the Safety and Immunogenicity of Repeated rhC1INH Administration of 50 U/Kg in Patients With Hereditary C1 Inhibitor Deficiency (HAE)

Trial Profile

An Open-label Exploratory Phase II Study of the Safety and Immunogenicity of Repeated rhC1INH Administration of 50 U/Kg in Patients With Hereditary C1 Inhibitor Deficiency (HAE)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions
  • Acronyms OPERA
  • Sponsors Pharming Group NV
  • Most Recent Events

    • 03 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top